除了真正的急性肾损伤（AKI）外，伪AKI的发生与几种靶向药物有关。为了改善接受靶向治疗的癌症患者的管理，我们需要意识到这一点，并使用诊断方法区分伪AKI和AKI。在本期CKJ中，Wijtvliet等人发表的一篇文章将tepotinib添加到与伪AKI相关的靶向药物清单中。在本篇社论中，我们讨论了有关靶向药物相关的伪AKI和真正的AKI的当前文献，并随后提出了一种监测接受靶向治疗患者的肾功能的管理策略。 © 作者 2023。由 ERA 代表牛津大学出版社出版。

Besides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated with several targeted agents. To improve the management of cancer patients treated with targeted agents, we need to be aware of this and use diagnostic approaches to differentiate between pseudo-AKI and AKI. In an article by Wijtvliet et al. in this issue of CKJ, tepotinib is added to the list of targeted agents associated with pseudo-AKI. In this editorial we discuss the current literature regarding pseudo-AKI and true AKI associated with targeted agents, and subsequently propose a management strategy to monitor kidney function in patients treated with targeted agents.© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.